NIPH Clinical Trials Search

UMIN ID: UMIN000000630

Registered date:31/12/2008

Voriconazole versus Micafungin for empirical antifungal therapy in patients with neutropenia and persistent fever

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedfebril neutropenia
Date of first enrollment2007/02/01
Target sample size100
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Micafugin150mg iv once a day Voriconazole 6mg/kg iv twice a day on day1,followed by 4mg/kg iv twice daily


Primary Outcomedefervesce and survival rate after two and four weeks from starting treatment
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum16years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteria1)AST/ALT/total bilirubin>5 times the upper limit of normal(at each institution).2)Karnofsky score<30%.3)Documented invasive fungal infection before starting treatment.4)History of treatment by voriconazole or mycafungin.5)History of allergy or hypersensitivity to voriconazole or mycafungin.6)Not eligible for the study in the opinion of investigators

Related Information


public contact
Address Japan
Telephone 019-651-5111
Affiliation Iwate Medical unversity Hematology
scientific contact
Name Yoji Ishida
Address 19-1 utimaru morioka Iwate Janpan Japan
Affiliation Iwate Medical unversity Hematology